EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors

Matthew E Campbell iD, Sonja Stutzman, Sharon Primeaux iD, Deseray Sida, Minjae Lee iD, Avanthi T Shah, Arhanti Sadanand iD, Elizabeth Sokol iD, Natalie B Collins, Brian Turpin iD, Shoba Navai iD, Katie Albert und 5 weitere

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.32046 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Matthew E Campbell und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local, Neoplasms, Rhabdomyosarcoma. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Children's Health, V Foundation, Wipe Out Kids' Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Combining immune checkpoint inhibitors (ICI) with chemotherapy may improve treatment response in children with solid tumors. We sought to determine the feasibility of combining vincristine, irinotecan, and temozolomide with the ICI atezolizumab in children with relapsed or refractory solid tumors (VITAS;).

Methods

Patients ≥6 months and ≤18 years old with a relapsed or refractory solid tumor, no prior ICI, and evaluable disease per RECIST v1.1 were eligible for the Phase I cohort (NCT04796012). Patients received atezolizumab 15 mg/kg on Day 1, vincristine 1.5 mg/m 2 on Day 1, irinotecan 50 mg/m 2 on Days 1–5, and temozolomide 100 mg/m 2 on Days 1–5 in 21‐day cycles. The primary endpoint was the number of patients with dose‐limiting toxicities (DLT) in the first two cycles of therapy.

Results

Six patients (median age: 14 years) with rhabdomyosarcoma ( n = 3), osteosarcoma ( n = 2), and Ewing sarcoma ( n = 1) received therapy and were evaluable for toxicity. Patients received a median of seven (range: 2–20) cycles of treatment. No patients experienced a DLT. One patient experienced Grade 2 immune‐related colitis. Four patients experienced Grade ≥3 adverse events (decreased neutrophil count, febrile neutropenia, weight loss, anorexia). One patient with rhabdomyosarcoma had a sustained partial response through 16 cycles. One patient with relapsed pulmonary osteosarcoma has ongoing stable disease through 20 cycles.

Conclusions

Atezolizumab combined with vincristine, irinotecan, and temozolomide was feasible and well tolerated in children with solid tumors. Efficacy of this regimen is now being assessed in relapsed and refractory rhabdomyosarcoma in an ongoing Phase II cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalNeoplasmsRhabdomyosarcomaHumansAdolescentChildMaleFemaleFeasibility StudiesAntibodies, Monoclonal, HumanizedIrinotecanTemozolomideVincristineChild, PreschoolFollow-Up StudiesPrognosisDrug Resistance, NeoplasmInfant

Stichwörter der Autor:innen

combination therapyimmunotherapyphase I trialsarcomasolid tumors

Substanzen

atezolizumabAntibodies, Monoclonal, HumanizedIrinotecanTemozolomideVincristine

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Health Data Science & Biostatistics, Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Division of Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
  • Pediatric Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Division of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.

ORCID-Profile: Matthew E Campbell, Sharon Primeaux, Minjae Lee, Arhanti Sadanand, Elizabeth Sokol, Brian Turpin, Shoba Navai, Dinesh Rakheja, Kenneth S Chen

Förderung

  • Children's Health
  • V Foundation
  • Wipe Out Kids' Cancer
  • University of Texas Southwestern Medical Center
  • Children's Cancer Fund
  • NIAID NIH HHS
  • Alex's Lemonade Stand Foundation for Childhood Cancer
  • V Foundation for Cancer Research

Zitieren

APA

Campbell, M. E., Stutzman, S., Primeaux, S., Sida, D., Lee, M., Shah, A. T., Sadanand, A., Sokol, E., Collins, N. B., Turpin, B., Navai, S., Albert, K., Laetsch, T. W., Rakheja, D., Chen, K. S., Gerber, D. E., & Koh, A. Y. (2025). Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32046

Vancouver

Campbell ME, Stutzman S, Primeaux S, Sida D, Lee M, Shah AT, et al. Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.32046

BibTeX
@article{Campbell2025,
  author = {Campbell, Matthew E and Stutzman, Sonja and Primeaux, Sharon and Sida, Deseray and Lee, Minjae and Shah, Avanthi T and Sadanand, Arhanti and Sokol, Elizabeth and Collins, Natalie B and Turpin, Brian and Navai, Shoba and Albert, Katie and Laetsch, Theodore W and Rakheja, Dinesh and Chen, Kenneth S and Gerber, David E and Koh, Andrew Y},
  title = {Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.32046}
}
Kostenlos starten →